In 2013, 2 Bridge was founded by four experienced drug developers with highly complementary skills. The initial team has grown significantly since its inception, from a small core team of four to a team of more than thirty highly educated scientists, experienced healthcare industry leaders, entrepreneurs, and young professionals.
biologist, Ph.D. in sciences
Managing Partner & Co-CEO
Ann holds a Ph.D. in Science from the University of Antwerp (Biology/Pharmacology) and a Master in Management from UA and Middle Management MBA from Vlerick Business School. Currently, she is the CEO, one of the managing partners, and co-founders of 2 Bridge.
Ann has extensive experience (30+ years) in drug development. In her previous role as a compound development team leader in a big pharma company, she brought several products from discovery to the early clinical proof of concept phase and subsequently led and managed the early development portfolio of a spinout company. Amongst others, Ann has guided a clinical-stage biotech as Chief Development Officer, while supporting several companies in evaluating, selecting, and developing products, often in interim management roles (CSO/CEO).
Managing Partner & Co-CEO
Tomas has more than 30 years of experience in financial management in both big multinationals and small, local companies covering a broad range of industries. After starting his career at Procter & Gamble, he turned to the pharma industry by joining Johnson & Johnson, where he held various financial roles in production and commercial organizations. Banking on that experience he became Finance Director at Movetis, a spin-off from Janssen Pharmaceutica. After that, Tomas held Finance Director and CFO roles in various Belgian companies with a focus on business partnership, process excellence, and strategic finance.
Currently, Tomas is CFO at 2 Bridge, AbolerIS Pharma, and DeuterOncology.
Managing Partner & COO
Birgen gained progressively experience (15 years) in Clinical Development, developing his career in both a CRO environment as well as in small biotech and large pharmaceutical companies. With his refined project and vendor management skills, Birgen successfully led global pivotal trials towards drug registration. He strives for efficiency by optimizing operating processes and by maximizing collaborators’ engagement while safeguarding quality and budget.
To date, he is mainly involved in overseeing the clinical operational management of the various trials within a drug development program.
PhD in medical sciences
Managing Partner & CSO
Leen has over twenty years of experience in Research and Development, from drug discovery to early clinical development. She previously worked at Johnson & Johnson, 4AZA-Elbion, Movetis, and Shire where she worked on a variety of projects in bringing compounds from target identification to clinical proof-of-concept, with a track record in translational strategy and personalized medicine, including biomarkers and patient-related outcomes.
Leen also acted as Chief Development Officer at Dynacure, where she established the basis of the overall development strategy for its lead program in CNM.
Upload your resume
Rodendijk 60 X
2980 Zoersel, Belgium
+32 (0) 3 296 01 51
General Inquiry: email@example.com
Job Opportunities: HR@2bridge.be
Service & Solution: BD@2bridge.be
2 Bridge NV is a recognized service provider for the KMO portefeuille (SME portfolio) for providing strategic advice(DV.A222333) and training (DV.O214140).
2 Bridge obtained the Crédit Impots Recherche (CIR) Accreditation for the years 2021, 2022, and 2023, an initiative of the French government to provide tax credit for R&D services.
© 2023 2 Bridge. website by EHBOntwerp